Angiovisium, Diagnostics and Solutions Limited 15204622 false 2024-11-01 2025-10-31 2025-10-31 The principal activity of the company is provision of specialists medical practice activities Digita Accounts Production Advanced 6.30.9574.0 true 15204622 2024-11-01 2025-10-31 15204622 2025-10-31 15204622 core:CurrentFinancialInstruments core:WithinOneYear 2025-10-31 15204622 bus:Micro-entities 2024-11-01 2025-10-31 15204622 bus:AuditExemptWithAccountantsReport 2024-11-01 2025-10-31 15204622 bus:FilletedAccounts 2024-11-01 2025-10-31 15204622 bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 15204622 bus:RegisteredOffice 2024-11-01 2025-10-31 15204622 bus:Director1 2024-11-01 2025-10-31 15204622 bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 15204622 countries:EnglandWales 2024-11-01 2025-10-31 15204622 2023-10-11 2024-10-31 15204622 2024-10-31 15204622 core:CurrentFinancialInstruments core:WithinOneYear 2024-10-31 iso4217:GBP xbrli:pure

Registration number: 15204622 (England & Wales)

Prepared for the registrar
Angiovisium, Diagnostics and Solutions Limited
Unaudited Financial Statements
for the Year Ended 31 October 2025

Angiovisium, Diagnostics and Solutions Limited

(Registration number: 15204622)
Balance Sheet as at 31 October 2025

| 2025 £ | 2024 £
Current assets | 31,032 | 13,595
Prepayments and accrued income | 4,378 | 2,536
Creditors: Amounts falling due within one year | (4,825) | (5,195)
Total assets less current liabilities | 30,585 | 10,936
Accruals and deferred income | (2,252) | (1,800)
| 28,333 | 9,136
Capital and reserves | 28,333 | 9,136

Angiovisium, Diagnostics and Solutions Limited

(Registration number: 15204622)
Balance Sheet as at 31 October 2025

| General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Windsor House
Bayshill Road
Cheltenham
Gloucestershire
GL50 3AT

Basis of preparation

The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Staff numbers

The average number of persons employed by the company (including directors) during the year, was as follows:

| Year ended 31 October 2025 No. | 11 October 2023 to 31 October 2024 No.
Average number of employees | 2 | 2

| Related party transactions

At 31 October 2025 the company owed the director Dr L M Fan £224 (2024: £2,698) in the form of a director's loan account. The loan is repayable on demand and no interest was paid in the year.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the micro entities regime and FRS 105 ‘The Financial Reporting Standard Applicable to the Micro-entities Regime.

For the financial year ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

Approved and authorised by the Board on 21 May 2026 and signed on its behalf by:

Dr L M Fan Director |  |